Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore-Reference-Cited by-同舟云学术

Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore

Published:2022-12-02 Issue:12 Volume:18 Page:805-815
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Yong Wei Peng¹,Teo Felicia SW²³,Teo Lynette LS⁴,Ng Matthew CH⁵,Tan Tira J.⁵,Low Su Ying⁶,Wong Karmen⁷,Ang Peter⁸,Choo Su Pin⁹,Lee Kim Hua¹⁰,Lee Soo Chin¹

Affiliation:

1. National University Cancer Institute, Singapore, National University Health System, Singapore

2. University Medicine Cluster, Division of Respiratory and Critical Care Medicine, National University Hospital, National University Health System, Singapore

3. The Lung Clinic, Mount Elizabeth Medical Centre, Singapore

4. Department of Diagnostic Imaging, National University Hospital, National University Health System, Singapore

5. Division of Medical Oncology, National Cancer Centre Singapore, Singapore

6. Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore

7. Icon Cancer Centre, Mount Alvernia Hospital, Singapore

8. Oncocare Cancer Centre, Mount Elizabeth Novena Medical Centre, Singapore

9. Curie Oncology, Mount Elizabeth Hospital, Singapore

10. Division of Oncology Nursing, National University Cancer Institute, Singapore, National University Health System, Singapore

Funder

AstraZeneca Singapore in accordance with

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2022.2162383

Reference80 articles.

1. Interstitial Lung Diseases in Developing Countries

2. An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease

3. Drug-Induced Interstitial Lung Disease: A Systematic Review

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database;Expert Opinion on Drug Safety;2024-09-12

2. Updates in the Use of Targeted Therapies for Gynecologic Cancers;American Society of Clinical Oncology Educational Book;2024-06

3. Bronchioalveolar organoids: A preclinical tool to screen toxicity associated with antibody-drug conjugates;Toxicology and Applied Pharmacology;2024-04

4. Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease;Drug Safety;2024-03-09

5. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system;International Journal of Clinical Pharmacy;2023-12-15